These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15626585)

  • 21. Study on dissolution and absorption of four dosage forms of isosorbide mononitrate: level A in vitro-in vivo correlation.
    Li ZQ; He X; Gao X; Xu YY; Wang YF; Gu H; Ji RF; Sun SJ
    Eur J Pharm Biopharm; 2011 Oct; 79(2):364-71. PubMed ID: 21569844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
    Niopas I; Daftsios AC; Nikolaidis N
    Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology.
    Verma RK; Kaushal AM; Garg S
    Int J Pharm; 2003 Sep; 263(1-2):9-24. PubMed ID: 12954176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Plasma levels of isosorbide dinitrate and its metabolites during intravenous infusion in surgical patients--effect of preoperative administration of isosorbide dinitrate].
    Murakawa T; Hashimoto Y; Sato T; Takagi H; Kushikata T; Araki I; Kou H; Kimura F; Matsuki A
    Masui; 1993 Feb; 42(2):225-32. PubMed ID: 8437354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
    Jin C; Jeon JY; Im YJ; Jeong JA; Kim Y; Chae SW; Bentz J; Kumke T; Kim MG
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):97-106. PubMed ID: 25492848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal delivery of isosorbide 5-mononitrate from a new membrane reservoir and matrix-type patches.
    Arra GS; Arutla S; Krishna DR
    Drug Dev Ind Pharm; 1998 May; 24(5):489-92. PubMed ID: 9876613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An extensive study on isosorbide-5-mononitrate acid adducts for quantification in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry and its application to bioequivalence sample analysis.
    Jain DS; Subbaiah G; Sanyal M; Shrivastav PS; Pal U; Ghataliya S; Kakad A; Bhatt J; Munjal V; Patel H; Shah S
    Rapid Commun Mass Spectrom; 2006; 20(19):2921-31. PubMed ID: 16941726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential usefulness of solubility index for prediction of the skin permeation rate of 5-ISMN from pressure-sensitive adhesive tape.
    Sato K; Mitsui N; Hasegawa T; Sugibayashi K; Morimoto Y
    J Control Release; 2001 Jun; 73(2-3):269-77. PubMed ID: 11516504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
    Muck B; Bonn R; Rietbrock N
    Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate.
    Liu Y; Liu S; Dai Q
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):55-60. PubMed ID: 19122316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
    Arthur RM; Mehmel H
    Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic fact of 14C-isosorbide 5-mononitrate in humans.
    Wood SG; John BA; Chasseaud LF; Major RM; Forrest ME; Bonn R; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(9):1031-5. PubMed ID: 6542370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
    Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D
    Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.